Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19

doi:10.1007/s11427-020-1732-2

	Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19
	Yu Bo 2,3; Li Chenze 2,3; Chen Peng 2,3; Zhou Ning 2,3; Wang Luyun 2,3; Li Jia 4; Jiang Hualiang 1,4,5; Wang Dao-Wen 2,3
刊名	SCIENCE CHINA-LIFE SCIENCES
	2020-05-15
页码	7
ISSN号	1674-7305
DOI	10.1007/s11427-020-1732-2
通讯作者	Wang Dao-Wen(dwwang@tjh.tjmu.edu.cn)
英文摘要	Coronavirus disease 2019 (COVID-19) is a pandemic with no specific drugs and high fatality. The most urgent need is to find effective treatments. We sought to determine whether hydroxychloroquine (HCQ) application may reduce the death risk of critically ill COVID-19 patients. In this retrospective study, we included 550 critically ill COVID-19 patients who need mechanical ventilation in Tongji Hospital, Wuhan, from February 1, 2020 to April 4, 2020. All 550 patients received comparable basic treatments including antiviral drugs and antibiotics, and 48 of them were treated with oral HCQ treatment (200 mg twice a day for 7-10 days) in addition to the basic treatments. Primary endpoint is fatality of patients, and inflammatory cytokine levels were compared between HCQ and non-hydroxychloroquine (NHCQ) treatments. We found that fatalities are 18.8% (9/48) in HCQ group, which is significantly lower than 47.4% (238/502) in the NHCQ group (P<0.001). The time of hospital stay before patient death is 15 (10-21) days and 8 (4-14) days for the HCQ and NHCQ groups, respectively (P<0.05). The levels of inflammatory cytokine IL-6 were significantly reduced from 22.2 (8.3-118.9) pg mL(-1) at the beginning of the treatment to 5.2 (3.0-23.4) pg mL(-1) (P<0.05) at the end of the treatment in the HCQ group but there is no change in the NHCQ group. These data demonstrate that addition of HCQ on top of the basic treatments is highly effective in reducing the fatality of critically ill patients of COVID-19 through attenuation of inflammatory cytokine storm. Therefore, HCQ should be prescribed as a part of treatment for critically ill COVID-19 patients, with possible outcome of saving lives. hydroxychloroquine, IL-6, mortalities, COVID-19
资助项目	Ministry of Science and Technology of China[2020YFC0844500] ; National Natural Science Foundation of China[31130031] ; Chinese Academy of Sciences[2020YJFK0105] ; Chinese Academy of Engineering and Ma Yun Foundation[2020-CMKYGG-05]
WOS关键词	CHLOROQUINE
WOS研究方向	Life Sciences & Biomedicine - Other Topics
语种	英语
出版者	SCIENCE PRESS
WOS记录号	WOS:000533450200001
内容类型	期刊论文
源URL	[http://119.78.100.183/handle/2S10ELR8/280299]
专题	中国科学院上海药物研究所
通讯作者	Wang Dao-Wen
作者单位	1.Shanghai Tech Univ, Shanghai Inst Adv Immunochem Studies, Shanghai 201210, Peoples R China 2.Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Div Cardiol,Dept Internal Med, Wuhan 430030, Peoples R China 3.Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Hubei Key Lab Genet & Mol Mech Cardiol Disorders, Wuhan 430030, Peoples R China 4.Chinese Acad Sci, State Key Lab Drug Res, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China 5.Shanghai Tech Univ, Sch Life Sci & Technol, Shanghai 201210, Peoples R China
推荐引用方式 GB/T 7714	Yu Bo,Li Chenze,Chen Peng,et al. Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19[J]. SCIENCE CHINA-LIFE SCIENCES,2020:7.
APA	Yu Bo.,Li Chenze.,Chen Peng.,Zhou Ning.,Wang Luyun.,...&Wang Dao-Wen.(2020).Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19.SCIENCE CHINA-LIFE SCIENCES,7.
MLA	Yu Bo,et al."Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19".SCIENCE CHINA-LIFE SCIENCES (2020):7.